Nijmegen

• Phase 3 Study of Tinlarebant in the Treatment in Adolescent Stargardt Subjects Ended
  2024-513483-26-00 5 2022-11-28 Stargardt Disease
• A study in people with systemic sclerosis to test whether BI 685509 has an effect on lung function and other systemic sclerosis symptoms Ended
  2022-500332-11-00 4 2022-11-25 systemic sclerosis
• Digoxin for the Reinduction or Radioiodine Uptake in Metastatic or Locally Advanced Non-medullary Thyroid Cancer. Ended
  2022-500477-14-00 4 2022-11-09 Non-medullary thyroid Carconoma (NMTC)
• VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended
  2022-500079-30-00 5 2022-11-03 IgA Nephropathy
• A Phase 3 study to determine the Efficacy and Safety of Losmapimod in Treating Patients with Facioscapulohumeral Muscular Dystrophy (REACH) Ended
  2024-512737-33-00 5 2022-09-30 Facioscapulohumeral Muscular Dystrophy (FSHD)
• Nivolumab during active surveillance after neoadjuvant chemoradiation for esophageal cancer: SANO-3 study Ended
  2024-513635-24-00 10 2022-09-29 oesophageal cancer
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to dalteparin … Ended
  2024-513992-42-00 10 2022-09-13 venous thromboembolism (VTE) in patients with gastrointestinal/genitou
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Pa … Ended
  2023-504412-14-00 3 2022-09-01 Early Idiopathic Parkinson’s Disease (PD)
• A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on … Ended
  2023-509569-19-00 10 2022-08-10 venous thromboembolism (VTE)
• A Study to Evaluate the Efficacy, Safety and Tolerability of a Single Injection of AC102 into the Middle Ear Compared to Oral Steroid Treatm … Ended
  2024-513658-31-00 4 2022-08-08 Idiopathic Sudden Sensorineural Hearing Loss
• First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leuk … Ended
  2023-508357-58-00 7 2022-07-04 Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myel
• A Study Evaluating Bemarituzumab in Solid Tumors with FGFR2b Overexpression Ended
  2023-505455-44-00 9 2022-06-29 Solid tumours
• A Phase 3 Study of Sotatercept in Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension (PAH) Patients. Ended
  2023-509139-16-00 5 2022-05-13 Therapeutic confirmatory (phase III)
• A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended
  2024-514372-40-00 5 2022-04-12 Anterior ST-Elevation Myocardial Infarction
• A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient … Ended
  2024-514130-20-00 5 2022-04-04 complement 3 glomerulopathy (C3G)/immune complex membranoproliferativ
• A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia. Ended
  2024-510696-38-00 5 2022-03-08 Severe Hypertriglyceridemia.
• A study to evaluate the efficacy and safety of olorofim versus AmBisome® for treatment of invasive aspergillosis Ended
  2024-513030-38-00 5 2022-02-15 Invasive fungal infections due to Aspergillus spp.
• Sarcomas and DDR-Inhibition; a neoadjuvant phase I combined modality study - SADDRIN-1 Ended
  2024-514907-32-00 3 2022-01-21 non-metastatic soft tissue sarcoma
• A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Mu … Ended
  2023-507189-17-00 4 2022-01-09 Muscle-Invasive Urothelial Carcinoma of the Bladder
• An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan … Ended
  2024-511544-36-00 4 2021-12-21 complement 3 glomerulopathy (C3G)/immune complex membranoproliferative
• GEN1047 for Solid Tumors - First in Human (FIH) Trial Ended
  2024-510722-10-00 7 2021-12-13 Malignant Solid Tumors
• An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects with Geographic Atrophy Secondary to … Ended
  2024-512945-18-00 5 2021-11-30 Geographic Atrophy Secondary to Age-Related Macular Degeneration
• LAVA1207-001/LAVA1207-002 A Phase 1 and 2a open-label trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immun … Ended
  2024-515821-27-00 9 2021-11-30 Prostate Cancer
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer

Showing 505–528 of 568 trials